214 related articles for article (PubMed ID: 35145077)
21. Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response.
Zheng Y; Wang Q; Li T; Qian J; Lu Y; Li Y; Bi E; Reu F; Qin Y; Drazba J; Hsi E; Yang J; Cai Z; Yi Q
J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27381622
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker.
Ryu D; Kim HJ; Joung JG; Lee HO; Bae JS; Kim SJ; Kim H; Park WY; Kim K
Oncotarget; 2016 Jul; 7(30):47127-47133. PubMed ID: 27223072
[TBL] [Abstract][Full Text] [Related]
23. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
Front Immunol; 2021; 12():792609. PubMed ID: 34880879
[TBL] [Abstract][Full Text] [Related]
24. Young female patients with multiple myeloma have low occurrence of osteolytic lesion.
Zhang D; Huang J; Zhang W; Pan L; Zhang D; Zhao P; Wang F; Luo H; He J; Qin Y; Qu Y; Guo T; Niu T; Zheng Y
Bone; 2018 May; 110():21-28. PubMed ID: 29414597
[TBL] [Abstract][Full Text] [Related]
25. Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma.
Waizenegger JS; Ben-Batalla I; Weinhold N; Meissner T; Wroblewski M; Janning M; Riecken K; Binder M; Atanackovic D; Taipaleenmaeki H; Schewe D; Sawall S; Gensch V; Cubas-Cordova M; Seckinger A; Fiedler W; Hesse E; Kröger N; Fehse B; Hose D; Klein B; Raab MS; Pantel K; Bokemeyer C; Loges S
Leukemia; 2015 Mar; 29(3):696-704. PubMed ID: 25102945
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis.
Yao L; Jayasinghe RG; Lee BH; Bhasin SS; Pilcher W; Doxie DB; Gonzalez-Kozlova E; Dasari S; Fiala MA; Pita-Juarez Y; Strausbauch M; Kelly G; Thomas BE; Kumar SK; Cho HJ; Anderson E; Wendl MC; Dawson T; D'souza D; Oh ST; Cheloni G; Li Y; DiPersio JF; Rahman AH; Dhodapkar KM; Kim-Schulze S; Vij R; Vlachos IS; Mehr S; Hamilton M; Auclair D; Kourelis T; Avigan D; Dhodapkar MV; Gnjatic S; Bhasin MK; Ding L
Cancer Res Commun; 2022 Oct; 2(10):1255-1265. PubMed ID: 36969740
[TBL] [Abstract][Full Text] [Related]
27. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
Groen RW; de Rooij MF; Kocemba KA; Reijmers RM; de Haan-Kramer A; Overdijk MB; Aalders L; Rozemuller H; Martens AC; Bergsagel PL; Kersten MJ; Pals ST; Spaargaren M
Haematologica; 2011 Nov; 96(11):1653-61. PubMed ID: 21828122
[TBL] [Abstract][Full Text] [Related]
28. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
[TBL] [Abstract][Full Text] [Related]
29. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma.
Paiva B; Pérez-Andrés M; Vídriales MB; Almeida J; de las Heras N; Mateos MV; López-Corral L; Gutiérrez NC; Blanco J; Oriol A; Hernández MT; de Arriba F; de Coca AG; Terol MJ; de la Rubia J; González Y; Martín A; Sureda A; Schmidt-Hieber M; Schmitz A; Johnsen HE; Lahuerta JJ; Bladé J; San-Miguel JF; Orfao A; ;
Leukemia; 2011 Apr; 25(4):697-706. PubMed ID: 21252988
[TBL] [Abstract][Full Text] [Related]
30. Expression of adhesion molecules in malignant plasma cells in multiple myeloma: comparison with normal plasma cells and functional significance.
Helfrich MH; Livingston E; Franklin IM; Soutar RL
Blood Rev; 1997 Mar; 11(1):28-38. PubMed ID: 9218104
[TBL] [Abstract][Full Text] [Related]
31. Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype.
Pope B; Brown R; Luo XF; Gibson J; Joshua D
Leuk Lymphoma; 1997 May; 25(5-6):545-54. PubMed ID: 9250826
[TBL] [Abstract][Full Text] [Related]
32. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
33. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
[TBL] [Abstract][Full Text] [Related]
34. [Role of bone marrow microenvironment in regulation of AP-1 gene expression in multiple myeloma cells].
Chen LJ; Xu JR; Zhou WH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):103-6. PubMed ID: 20137127
[TBL] [Abstract][Full Text] [Related]
35. The cellular architecture of multiple myeloma.
Vicente-Dueñas C; Romero-Camarero I; García-Criado FJ; Cobaleda C; Sánchez-García I
Cell Cycle; 2012 Oct; 11(20):3715-7. PubMed ID: 22983005
[No Abstract] [Full Text] [Related]
36. Plasma cell morphology in multiple myeloma and related disorders.
Ribourtout B; Zandecki M
Morphologie; 2015 Jun; 99(325):38-62. PubMed ID: 25899140
[TBL] [Abstract][Full Text] [Related]
37. The oncoprotein phenotype of plasma cells from patients with multiple myeloma.
Brown RD; Pope B; Luo XF; Gibson J; Joshua D
Leuk Lymphoma; 1994 Dec; 16(1-2):147-56. PubMed ID: 7696921
[TBL] [Abstract][Full Text] [Related]
38. [Bone marrow plasma concentrations of Dickkopf1 in patients with multiple myeloma].
Dun XY; Jiang H; Hou J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 38(5):453-8. PubMed ID: 19830856
[TBL] [Abstract][Full Text] [Related]
39. Myeloma cells self-promote migration by regulating TAB1-driven TIMP-1 expression in mesenchymal stem cells.
Rethnam M; Tan DQ; Suda T
Biochem Biophys Res Commun; 2021 Jan; 534():843-848. PubMed ID: 33183761
[TBL] [Abstract][Full Text] [Related]
40. Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities.
Kriegova E; Fillerova R; Minarik J; Savara J; Manakova J; Petrackova A; Dihel M; Balcarkova J; Krhovska P; Pika T; Gajdos P; Behalek M; Vasinek M; Papajik T
Sci Rep; 2021 Jul; 11(1):14671. PubMed ID: 34282158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
